ENGASE: A Potential Drug Target for Disaccharide-Binding Enzymes

Target Name: ENGASE

NCBI ID: G64772

ENGASE

ENGASE: A Potential Drug Target for Disaccharide-Binding Enzymes

ENGASE (Endo-N-acetyl-beta-D-glucosaminidase) is an enzyme that plays a crucial role in the breakdown of a type of sugar called disaccharide, which is a key component of many different types of cells in the body. ENGASE is Highly expressed in many tissues and is involved in a wide range of cellular processes, including cell signaling, inflammation, and tissue repair.

One of the reasons why ENGASE is a potential drug target is that it is highly mutated in many diseases, including cancer. Many studies have shown that ENGASE gene mutations are highly associated with poor prognosis in a variety of diseases, including breast, ovarian, and colorectal cancers. Additionally, ENGASE has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease.

Another potential reason why ENGASE is a drug target is that it is involved in the production of many different types of proteins, including extracellular matrix (ECM) proteins. ECM proteins are important for cell signaling, tissue structure, and repair, and have been shown to be involved in many different diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. ENGASE is involved in the production of several ECM proteins that have been implicated in disease progression, including extracellular matrix subjects (ECM-T), which are important for tissue repair and regeneration.

ENGASE is also involved in the production of many different types of signaling proteins, including cytokines and growth factors. These proteins are important for cell signaling and have been shown to be involved in many different diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. ENGASE is involved in the production of several signaling proteins, including transforminger-1 (TGF-1), which is a key signaling protein involved in cancer progression and neurodegenerative diseases.

ENGASE is also involved in the production of many different types of enzymes that are involved in the metabolism of the immune system. These enzymes are important for immune surveillance and have been shown to be involved in many different diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. ENGASE is involved in the production of several immune-related enzymes, including natural killer (NKG) killer cells and T-cells.

In conclusion, ENGASE is a versatile enzyme that is involved in a wide range of cellular processes in the body. Its mutational status and involvement in the production of many different types of proteins and signaling proteins make it a promising drug target for a variety of diseases . Further research is needed to fully understand the role of ENGASE in disease progression and to develop effective treatments.

Protein Name: Endo-beta-N-acetylglucosaminidase

Functions: Endoglycosidase that releases N-glycans from glycoproteins by cleaving the beta-1,4-glycosidic bond in the N,N'-diacetylchitobiose core. Involved in the processing of free oligosaccharides in the cytosol

The "ENGASE Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ENGASE comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets